Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tapan M. Kadia"'
Publikováno v:
Haematologica.
The last decade has seen a steadfast progression in drug development in acute myeloid leukemia (AML) which have moved progressively towards genomics-based therapy. With these advancements, outcomes in AML have improved but remains far from satisfacto
Autor:
Guillaume Richard-Carpentier, Caitlin R. Rausch, Koji Sasaki, Danielle Hammond, Kiyomi Morita, Koichi Takahashi, Guilin Tang, Rashmi Kanagal-Shamanna, Kapil Bhalla, Courtney D. Dinardo, Gautam Borthakur, Naveen Pemmaraju, Elizabeth J. Shpall, Amin Alousi, Naval G. Daver, Guillermo Garcia-Manero, Marina Y. Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia
Publikováno v:
Haematologica.
Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) has a very poor prognosis. Determinants of clinical outcomes and optimal treatment remain uncertain. We retrospectively reviewed 108 cases of AML with inv(3)/t(3;3) and evaluated cl
Autor:
William R. Wilson, Naval Daver, Peter F. Thall, Hagop M. Kantarjian, Tapan M. Kadia, Naveen Pemmaraju, Jennie Feliu, Andrew Coveler, John Gutheil, Sergej Konoplev, Caimiao Wei, Carlos E. Bueso-Ramos, Stefan Faderl, Hongbo Lu, Cecilia Arana Yi, Hoang Q. Nguyen, Juliana Benito, Farhad Ravandi, Jorge E. Cortes, Deborah A. Thomas, Yongchuan Gu, Michael Andreeff, Teresa J. Melink, Marina Konopleva, Elihu H. Estey, Elias Jabbour, Steven M. Kornblau, Gautam Borthakur
Publikováno v:
Haematologica. 100:927-934
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-1
Autor:
Naval Daver, Elias Jabbour, Gautam Borthakur, Xuemei Wang, Sherry Pierce, Naveen Pemmaraju, Lingsha Zhou, Kate J. Newberry, Koji Sasaki, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia, Srdan Verstovsek, Farhad Ravandi
Publikováno v:
Haematologica.
Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibro